DUBLIN--(BUSINESS WIRE)--The "T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
'T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2017'; T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T cells. It co-stimulates signals required for T cell activation and survival. It enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L co-stimulation.
The report 'T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2017' outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
Key Topics Covered:
- Introduction
- T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Overview
- T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Companies Involved in Therapeutics Development
- Atox Bio Ltd
- Bristol-Myers Squibb Co
- Five Prime Therapeutics Inc
- Johnson & Johnson
- TheraMAB LLC
For more information about this report visit https://www.researchandmarkets.com/research/rmx3jp/t_cell_specific
